Loncastuximab Tesirine

Definition

An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody conjugated, via a cleavable linker comprised of valine-alanine and maleimide, to a cytotoxic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer, which targets DNA minor grooves, with potential antineoplastic activity. Upon administration, the monoclonal antibody portion of loncastuximab tesirine targets the cell surface antigen CD19 on various cancer cells. Upon antibody/antigen binding and internalization, the cytotoxic PBD moiety is released. The imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD19-overexpressing tumor cells. CD19, a transmembrane receptor and tumor-associated antigen (TAA), is expressed on a number of B-cell-derived cancers.

Also known as ADC ADCT-402, ADCT 402, ADCT-402, ADCT402, Anti-CD19 PBD-conjugate ADCT-402, LONCASTUXIMAB TESIRINE, Loncastuximab Tesirine-lpyl, MT 2111, MT-2111, MT2111, Zynlonta — per NCIT

Also identified as

• ATC L01FX22 per RXNORM
• NCIT NCIT:C125549 per NCIT
• SCTID 1157143009 per RXNORM
• SCTID 1157144003 per RXNORM
• UNII 7K5O7P6QIU per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.